What I’m Reading in APS Research, written by Dr. Ajay Tambralli, was created to provide information about some of the latest APS research and to help everyone better understand the ins and outs of new discoveries. In this month’s edition, Dr. Tambralli explores the amazing properties of camelid antibodies and their potential applications in future therapies.

In 1994, Mark Hall was diagnosed with antiphospholipid syndrome (APS).

The immune system is showing evidence of playing a roll in the emergence of atherosclerotic cardiovascular disease. A rush of neutrophils, or immune cells to the site could be an explanation for how this condition forms as well as how to prevent this heart disease in the future.

Dr. Jacqueline Madison, a dual adult and pediatric rheumatologist, is a member of the Childhood Arthritis and Rheumatology Research Alliance (CARRA), an organization that unites North American rheumatologists focused on pediatric rheumatology research. This year, Dr. Madison had the opportunity to organize and lead the APS Workgroup at CARRA’s Annual Scientific Meeting.

In this edition of the APS Program Community Q&A Series, Dr. Ray Zuo and Dr. Lauren Shevell explore GLP-1 drugs, how they work, and whether they are a safe option for people with APS.

Congratulation to Dr. Jacqueline Madison who received the Department of Pediatrics Chairs Award - Early Career Research Award.